Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of diabetic patients based on their cognitive status

Abstract

ABSTRACTAimType 2 diabetes mellitus (DM) increases the risk of dementia. We aimed to elucidate the dynamics of blood biomarkers according to the severity of cognitive impairment in patients with DM and to identify useful biomarkers for diabetes-related dementia.MethodsThis was a cross-sectional, nested case-control study of 121 Japanese diabetic and nondiabetic patients with different levels of cognitive functioning. We evaluated participants’ cognitive functions, blood biomarkers related to Alzheimer’s disease, and soluble triggering receptors expressed on myeloid cells 2 (sTREM2). We then compared these biomarkers between the DM and non-DM groups and across the different cognitive strata.ResultsSignificantly lower levels of serum sTREM2 were observed in the DM than in the non-DM patients. This was true across all the cognitive strata of the two groups, including those with normal cognition. We also found that plasma levels of phosphorylated tau 181 (p-tau181) increased with increasing levels of cognitive decline in both the DM and non-DM groups. However, this was accompanied by a decrease in plasma amyloid-β (Aβ)42/Aβ40 ratios in non-DM patients only.ConclusionThis study revealed novel characteristic trajectories of dementia-related blood biomarkers in diabetes-related dementia, suggesting the pathological involvement of molecular cascades initiated by impaired microglial activation. This results in decreased serum sTREM2, followed by tauopathy without substantial amyloid plaques, reflected by plasma p-tau elevation with no decrease in the Aβ42/Aβ40 ratio. Our results warrant further research into this molecular cascade to elucidate pathogenetic mechanisms of diabetes-related dementia and establish useful biomarkers.